The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Open accessAbstract
This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic AL amyloidosis evaluated the recommended (maximum planned) doses identified in phase 1 testing (1.6 mg/m2 once weekly [days 1, 8, 15, and 22; 35-day cycles]; 1.3 mg/m2 twice weekly [days 1, 4, 8, and 11; 21-day cycles]). Among all 70 patients enrolled in the study, 44% had ≥ 3 organs involved, including 73% and 56% with renal and cardiac involvement. In the 1.6 mg/m2 once-weekly and 1.3 mg/m2 twice-weekly groups, the hematologic response rate was 68.8% and 66.7% (37.5% and 24.2% complete responses, respectively); median time to first/best response was 2.1/3.2 and 0.7/1.2 months, and 78.8% and 75.5% had response durations of ≥ 1 year, respectively. One-year hematologic progression-free rates were 72.2% and 74.6%, and 1-year survival rates were 93.8% and 84.0%, respectively. Outcomes appeared similar in patients with cardiac involvement. Among all 70 patients, organ responses included 29% renal and 13% cardiac responses. Rates of grade ≥ 3 toxicities (79% vs 50%) and discontinuations/dose reductions (38%/53% vs 28%/22%) resulting from toxicities appeared higher with 1.3 mg/m2 twice-weekly versus 1.6 mg/m2 once-weekly dosing. Both bortezomib dose schedules represent active, well-tolerated regimens in relapsed AL amyloidosis. This study was registered at www.clinicaltrials.gov as #NCT00298766.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citation
Cited by
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Comenzo, R. L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V, Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.100 · Cited by 390
Self-citationMuchtar, E., Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dingli, D., Buadi, F. K., Grogan, M., Hayman, S. R., Kapoor, P., Leung, N., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751628 · Cited by 340
Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Muchtar, E., Blauwet, L. A., & Gertz, M. A. (2017) · Circulation Research · doi:10.1161/circresaha.117.310982 · Cited by 327
How I treat monoclonal gammopathy of renal significance (MGRS)
Fermand, J.-P., Bridoux, F., Kyle, R. A., Kastritis, E., Weiss, B. M., Cook, M. A., Drayson, M. T., Dispenzieri, A., & Leung, N. (2013) · Blood · doi:10.1182/blood-2013-05-495929 · Cited by 326
Self-citation
Metadata
- Authors
- Reece, D. E., Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G., Bladé, J., Fermand, J.-P., Hassoun, H., Heffner, L., Vescio, R. A., Liu, K., Enny, C., Esseltine, D.-L., van de Velde, H., Cakana, A., & Comenzo, R. L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-07-28
- Volume
- 118
- Issue
- 4
- Pages
- 865-873
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2077918440
- Cited by
- 168
- References
- 1
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. https://app.cochat.ai/papers/10.1182/blood-2011-02-334227
- The paper
- Reece, D. E., Hegenbart, U., Sanchorawala, V., Merlini, G., Palladini, G., Bladé, J., Fermand, J.-P., Hassoun, H., Heffner, L., Vescio, R. A., Liu, K., Enny, C., Esseltine, D.-L., van de Velde, H., Cakana, A., & Comenzo, R. L. (2011). Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. https://doi.org/10.1182/blood-2011-02-334227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.